Enveric Biosciences, Inc. · NASDAQ:ENVB
Enveric Biosciences — Investor Presentation (August 2024)
15 slides from Enveric Biosciences's investor presentation, Aug 21, 2024
Slide 1: Corporate Presentation Q3 2024
:ENVB CORPORATE PRESENTATION Q3 2024 Enveric.com
Slide 2: Disclaimer
Disclaimer No Offer or Solicitation This communication is for informational purposes only and is not intended to and does not constitute an offer to sell, or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. It does not constitute a prospectus or prospectu
Slide 3: Next Generation Mental Health
Next Generation TM Mental Health
Slide 4: Significant Global Health Issues: Depression, Anxiety & PTSD
Significant Global Health Issues: Depression, Anxiety & PTSD WIDESPREAD LOW EFFICACY 65 million in the US 40% 1 billion globally Experience a neuropsychiatric First line SSRI treatments work disorder at some time in their lives for less than half of patients Source: (NIMH) (SingleCare) (World Health
Slide 5: Neuroplastogens: A New Class of Drugs
Neuroplastogens: A New Class of Drugs Prefrontal Cortex Healthy Brain: Neurons in the prefrontal cortex (PFC) regulate emotional behavior via Top-Down control of the amygdala. Neuroplastogens stimulate Neuropsychiatric Illness: Reduced neuroplasticity in the PFC, which restores This modulates the fi
Slide 6: Psychedelic Neuroplastogen Drawbacks
Psychedelic Neuroplastogen Drawbacks: • Current neuroplastogens in clinical trials cause hallucinations in the patient • Require 8 hrs in-clinic treatment with two healthcare providers present, plus pre and post treatment counselling • Require psychotherapy as part of the treatment paradigm • Expens
Slide 7: EB-003: Non-Hallucinogenic Neuroplastogen Discovered in 1,000+ Molecule Library
EB-003: Non-Hallucinogenic O F Neuroplastogen Discovered in 1,000+ Molecule Library • Integrated synthetic biology and chemistry to create new library F F • Designed molecules based on natural serotonin receptor ligands HO F CI • Screened 1,000+ molecules for optimal drug candidate CI • Best molecul
Slide 8: EB-003: A New Treatment Standard
EB-003: A New Treatment Standard Psychedelic SSRI & SNRI EB-003 Neuroplastogens Immediate efficacy Low side effects No sexual dysfunction Does not cause weight gain Treatment in-clinic not required Large patient population Induces neuroplasticity in brain :ENVB
Slide 9: EB-003: Development Underway
EB-003: Development Underway Synopsis of Target Benefits • Reduced hallucination profile, treatment in clinic not required • Lower side effects • Rapid acting • Orally bioavailable • Intended to be prescribed for regular maintenance and taken at times and in settings convenient to patient 2024 2025
Slide 10: Market Potential: Redefining the Treatment Landscape for Mental Health Disorders
Market Potential: Redefining the Treatment Landscape for Mental Health Disorders Current SSRI/SNRI EB-003: A Breakthrough Predicted Neuroplastogen Market: Neuroplastogen Market: $20 Billion $35.4 Billion Neuroplastogen drug market anticipated by 2030 Leading Neuroplastogen Source: Coherent Market In
Slide 11: Additional Assets Leveraged from Discovery Platform
:ENVB Additional Assets Leveraged from Discovery Platform • Portfolio of 1,000+ novel drug candidates • 23 issued patents & 60 pending patent applications • Numerous distinct assets available for partnering or out- licensing • Multiple future revenue streams possible :ENVB
Slide 12: Partnering & Licensing
Partnering & Licensing Total Possible Royalty Rates Partner / Licensee Milestone Payments Assets for Partnering Partner EB-003 Available EB-002 Available Assets for Out-Licensing Licensee Topical Product for Radiation Tiered $61 Million License Agreement with Aries Science & Technology Dermatitis 2.
Slide 13: Management
Management Management Team Board of Directors Scientific Advisors Joseph Tucker, Ph.D. Michael D. Webb Maurizio Fava, M.D. CEO & Director Board Chair Scientific Advisor George Kegler Stephen M. Stahl, M.D. Director, Chair of the Audit Committee Scientific Advisor Kevin Coveney, CPA John Krystal, M.D
Slide 14: Potential First in Class Entrant to Large Mental Health Market
Potential First in Class Entrant to Large Mental Health Market EB-003: A Paradigm Shifting Drug Candidate • EB-003 is one of the leading neuroplastogen drug candidates • Anticipate human studies start by end of 2025 with value inflection data readouts during 2026 New Drug Class Market Opportunity •
Slide 15: Enveric Biosciences
Nasdaq :ENVB Mental Health™ BIOS CIENCES Enveric.com
Enveric Biosciences — Investor Presentation (August 2024) on 6ix